$BCLI to Announce #TopLine #Results #US #Phase2 #Study of #NurOwn in #ALS

Conference Call and Live Webcast at 10am Eastern Time

HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 14, 2016 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the recently completed Phase 2 Study of NurOwn® in Patients with ALS on Monday, July 18, 2016.  The Company will host a conference call and webcast with slides at 10:00am Eastern Time.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn®technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn®has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company’s website at www.brainstorm-cell.com.

CONTACTS

Media:
Uri Yablonka, COO
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com